Ospedale Civile SS. Annunziata
- Address
- lock Available on a paid plan
Ospedale Civile SS. Annunziata - Oncology Research Center
Ospedale Civile SS. Annunziata is a specialized clinical research center focused on advancing treatment strategies for thoracic malignancies. The center demonstrates particular expertise in investigating targeted therapies for non-small-cell lung cancer (NSCLC), with emphasis on personalized medicine approaches for patients with specific genetic mutations.
- EGFR mutation-positive advanced and metastatic NSCLC treatment optimization
- Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) sequencing strategies
- Targeted therapy trials for patients with classical and uncommon activating EGFR mutations
- Management of lung cancer patients with brain metastases
The institution conducts sophisticated phase II randomized trials to determine optimal treatment sequences using novel EGFR-TKIs including dacomitinib and osimertinib. Their research portfolio includes studies addressing challenging patient populations, such as those with asymptomatic or controlled brain metastases, contributing valuable evidence to guide clinical decision-making in precision oncology.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Fondazione Ricerca Traslazionale1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Ospedale Civile SS. Annunziata
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase II Randomized Study on EGFR-TKI Sequencing with Dacomitinib and Osimertinib in Advanced EGFR-Mutant NSCLC | Fondazione Ricerca Traslazionale | Phase II | Not Yet Recruiting | Mar 2020 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dacomitinib | 1 | Unknown | 2020-03-10 | 2020-03-10 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.